Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objectives of this study are: • To assess the ORR (complete response + partial response [CR + PR]) of E7080 in subjects with unresectable stage III or stage IV melanoma not harboring the V600E BRAF mutation and disease progression following first-line standard of care therapy (Cohort 1). • To assess the ORR of E7080 in subjects with unresectable stage III or stage IV melanoma harboring the V600E BRAF mutation and disease progression following BRAF-V600E-targeted therapy (Cohort 2).
Critère d'inclusion
- American Joint Committee on Cancer unresectable stage III or stage IV melanima and disease progression with subjects not harboring the V600E-BRAF mutation with disease progression following first line standard of care (cohort 1) or subjects harboring the V600E-BRAF mutation with disease progression following BRAF-V600E-targeted therapy (cohort 2)